At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Feasibility Study of Xofluza Treatment of Influenza in Pediatric Transplant Recipients, Waitlisted Subjects and Household Members After Early Infection Alerting Using Wearable Devices
In Brief
A Phase 4 clinical trial evaluating Baloxavir Marboxil for Infection, Coronavirus and 4 related conditions. Completed, enrolled 498 participants across 1 site.
Detailed Summary
The goal of this prospective, interventional, single-center study is to assess whether the early detection of Influenza with smart wearable device algorithms and alerting, rapid testing, and subsequent Baloxavir treatment demonstrate better post-infection outcomes versus publicly available- and Centers for Disease Control (CDC)-derived national statistics for equivalent household populations as well as pediatric kidney, heart, liver, lung transplant recipients and waitlisted patients.
Study Details
Timeline
Interventions
Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight: 40 mg for a participants weighing 20-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg